Price
CHART BY
Frequently asked questions
What is Kalvista's market capitalization?
The market capitalization of Kalvista is $1.44B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Kalvista?
Kalvista's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -4.00. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Kalvista's stock?
Currently, 1 analysts cover Kalvista's stock, with a consensus target price of $27.00. Analyst ratings provide insights into the stock's expected performance.
What is Kalvista's revenue over the trailing twelve months?
Over the trailing twelve months, Kalvista reported a revenue of $1.43M.
What is the EBITDA for Kalvista?
Kalvista's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$201.82M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Kalvista?
Kalvista has a free cash flow of -$167.89M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Kalvista have, and what sector and industry does it belong to?
Kalvista employs approximately 275 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Kalvista's shares?
The free float of Kalvista is 43.18M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.44B
- EPS (TTM)
- -4.00
- Free Float
- 43.18M
- Revenue (TTM)
- $1.43M
- EBITDA (TTM)
- -$201.82M
- Free Cashflow (TTM)
- -$167.89M
Analyst Ratings
The price target is $27.00 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
- Employees
- 275
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- KALV
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet